[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507951":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":17,"locations":26,"responsibleParty":60,"collaborators":7,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":7,"enrollmentInfo":72,"targetDuration":7,"studyType":75,"phases":7,"briefSummary":76,"conditions":77,"keywords":7,"overallStatus":29,"whyStopped":7,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Insel Gruppe AG, University Hospital Bern","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Voice recording, ENT (Ear, Nose and Throat) examination including transnasal fiberendoscopy, and VHI-30-questionnaire","The following speech samples will be recorded from the study participants:\n\n* Standardized, phonetically balanced text\n* Sustained, modulated production of five vowels\n* Picture description\n* Diadochokinetic exercise.\n\nBefore starting speech recording, the participant fills in a questionnaire consisting of:\n\n* Health barometer\n* Self-rating in terms of stress\u002Ffatigue\u002Femotional status.\n\nAn Ear, Nose and Throat examination incl. transnasal fiberendoscopy is performed at each visit. The investigators will assess the vocal folds\u002Faryepiglottic folds for the presence of paralysis or reduced mobility, as well as the presence of scar\u002Fsynechia, edema, erythro-\u002Fleukoplakia, or a cancer-suspicious lesion\u002Fmass in the larynx\u002Fhypopharynx or a chondroradionecrosis in the larynx.\n\nAdditionally, it will be assessed, if a tracheotomy canula or a nasogastric tube is in place or was used since the last visit.\n\nFurthermore, the investigators will ask the patients to fill out the VHI-30.",[13],{"name":14,"affiliation":15,"role":16},"Roland Giger, Prof.","Inselspital, Bern University Hospital","PRINCIPAL_INVESTIGATOR",[18,22],{"name":14,"role":19,"phone":20,"phoneExt":7,"email":21},"CONTACT","+41 31 632 29 31","roland.giger@insel.ch",{"name":23,"role":19,"phone":24,"phoneExt":7,"email":25},"Miranda Visini, Dr. med.","+41 31 632 88 59","miranda.visini@insel.ch",[27,45],{"facility":28,"status":29,"city":30,"state":7,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Inselspital, Bern University Hospital","RECRUITING","Bern","3010","Switzerland","CH",{"type":35,"coordinates":36},"Point",[37,38],7.44744,46.94809,{"lat":38,"lon":37},[41,42,43],{"name":14,"role":19,"phone":20,"phoneExt":7,"email":21},{"name":23,"role":19,"phone":24,"phoneExt":7,"email":25},{"name":44,"role":16,"phone":7,"phoneExt":7,"email":7},"Roland Giger, Prof. Dr. med.",{"facility":46,"status":29,"city":47,"state":7,"zip":48,"country":32,"countryCode":33,"cosmosGeoPoint":49,"geoPoint":53,"contacts":54},"Department of Oto-Rhino-Larnygology, Head and Neck Surgery, University Hospital Zurich","Zurich","8091",{"type":35,"coordinates":50},[51,52],8.55,47.36667,{"lat":52,"lon":51},[55,59],{"name":56,"role":19,"phone":57,"phoneExt":7,"email":58},"Simon Müller, Dr. med.","+41 44 255 58 50","simon.mueller@usz.ch",{"name":56,"role":16,"phone":7,"phoneExt":7,"email":7},{"type":61,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100507951","the-voice-as-a-tool-to-detect-recurrence-of-laryngeal-and-hypopharyngeal-cancer-100507951",false,"NCT05894070","The Voice as a Tool to Detect Recurrence of Laryngeal and Hypopharyngeal Cancer","The Voice as a Tool to Detect Recurrence of Laryngeal and Hypopharyngeal Cancer (VoiceDetect) - a Feasibility Study","VoiceDetect","Inclusion Criteria:\n\n1. Histopathologically proven carcinoma in-situ or invasive LSCC or HPSCC (in non-surgically treated carcinoma: clinical\u002Fradiologic stage I-IV (excluding M1) according to the Union for International Cancer Control (UICC) \u002F Tumor (T), Nodes (N), and Metastases (M) (TNM) 8th ed.; in surgically treated carcinoma: pathological stage I-IV (excluding M1) according to the UICC \u002F TNM 8th ed.).\n2. ≥ 18 years of age.\n3. Treatment with curative intent, regardless of treatment modality (mono- or multimodal).\n\n   Remark: Patients with synchronous (larynx and hypopharynx included) or metachronous (before\u002Fafter the diagnosis of LSCC\u002FHPSCC) non-laryngeal\u002F-hypopharyngeal malignant non-metastatic tumors, with clinically confirmed complete remission 6 months after treatment and life expectancy of at least 6 months are eligible. Patients with surgically treated Tis-2 N0 M0 squamous cell carcinoma and\u002For basal cell carcinoma of the skin and\u002For other surgically treated non-head and neck Tis are eligible, although the treatment was within the 6 months before enrolment.\n4. Clinical confirmation of complete remission of LSCC or HPSCC through Ear, Nose and Throat (ENT) examination, including fiberendoscopy of the pharynx and larynx, at the time of enrolment, during the period of eligibility (6 to 30 months after treatment).\n\n   Remark: Patients with synchronous (larynx and hypopharynx included) or metachronous (before\u002Fafter the diagnosis of LSCC\u002FHPSCC) non-laryngeal\u002F-hypopharyngeal malignant non-metastatic tumors, with clinically confirmed complete remission 6 months after treatment and life expectancy of at least 6 months are eligible. Patients with surgically treated Tis-2 N0 M0 squamous cell carcinoma and\u002For basal cell carcinoma of the skin and\u002For other surgically treated non-head and neck Tis are eligible, although the treatment was within the 6 months before enrolment.\n5. Informed consent as documented by signature.\n\nExclusion Criteria:\n\n1. Total laryngectomy as primary therapy.\n2. Any local, regional, and systemic laryngeal or hypopharyngeal cancer persistence\u002Fprogression, or recurrence before enrolment.\n\n   Excepted: Patients with synchronous laryngeal\u002Fhypopharyngeal malignant non-metastatic tumors, with clinically confirmed complete remission 6 months after treatment and life expectancy of at least 6 months are eligible.\n3. Any local, regional, and systemic tumor persistence\u002Fprogression, or recurrence of synchronous (larynx and hypopharynx included) or metachronous (before\u002Fafter the diagnosis of LSCC\u002FHPSCC) non-laryngeal\u002F-hypopharyngeal malignant tumors within 6 months before enrolment.\n\n   Excepted: Patients with surgically treated progredient or recurrent locally defined Tis-2 N0 M0 squamous cell carcinoma and\u002For basal cell carcinoma of the skin and\u002For non-head and neck progredient or recurrent Tis.\n4. Any previously treated LSCC\u002FHPSCC or treated second primary malignancies of the larynx or hypopharynx before the diagnosis and treatment of the investigated LSCC\u002FHPSCC (= index tumor).\n5. Presence of any medical, psychological, familial, sociological, or geographical conditions expected to potentially hamper the compliance with the study protocol.\n6. Inability to follow procedures (e.g., inability to read) or insufficient knowledge of any project language (German and French).","ALL","18 Years",{"count":73,"type":74},100,"ESTIMATED","OBSERVATIONAL","The investigators will obtain three-monthly voice recordings and fiberendoscopic examinations of the larynx\u002Fhypopharynx for a minimal period of 6 months from all laryngeal\u002Fhypopharyngeal squamous cell carcinoma (LSCC\u002FHPSCC) patients, who have successfully completed curative primary treatment, except those who underwent total laryngectomy. Furthermore, the investigators will ask the patients to fill out the voice handicap index-30 questionnaire (VHI-30) during each study visit. The VHI-30 allows to make a subjective assessment of the patients' own vocal problem. The primary objective is to assess the feasibility and compliance of longterm regular voice monitoring in LSCC and HPSCC follow-up.",[78,79],"Laryngeal Cancer","Hypopharyngeal Cancer","2025-07-24",{"date":82,"type":83},"2025-07-29","ACTUAL",{"date":85,"type":83},"2023-08-02",{"date":87,"type":74},"2026-06-30",{"name":5,"class":6},2]